Company profile
Abologix company profile
ABOLOGIX is developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein. The treatment is designed for patients that do not respond to traditional cancer therapies.
Business identity
- Website
- https://abologix.com/
- Contact email
- [email protected]
- Phone number
- + 41 (022) 8801010
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $0+
- Founded
- 2018-02-02
Headquarters
- Headquarters
- Plan-les-Ouates, Geneva, Switzerland
- Postal code
- 1228
- Country code
- CH
- Continent
- Europe